查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
呼吸道疾病基因检测市场 - 全球和区域分析：按产品、按疾病类型、按技术、按性状类型、按年龄组、按最终用户、按国家分析：分析和预测（2023-2033）
市场调查报告书
商品编码
1375827

呼吸道疾病基因检测市场 - 全球和区域分析：按产品、按疾病类型、按技术、按性状类型、按年龄组、按最终用户、按国家分析：分析和预测（2023-2033）

Respiratory Disease Genetic Testing Market - A Global and Regional Analysis: Focus on Offerings, Specialty Type, Trait Type, Test Type Technology, Age Group, End User, and Country Analysis - Analysis and Forecast, 2023-2033
出版日期: 按订单生产 | 出版商: BIS Research | 英文 | 商品交期: 7-10个工作天内

价格
简介目录

呼吸系统疾病仍然是全球健康问题，对患者福祉和医疗保健系统产生重大影响。

基因检测已成为了解各种呼吸道疾病遗传背景的重要工具。

呼吸系统疾病是一组不同的疾病，包括气喘、慢性阻塞性肺病(COPD)、囊肿纤维化和间质性肺病。遗传学在呼吸系统疾病发生和进展中的作用越来越明显，基因检测在诊断、治疗和预防中的重要性日益凸显。

基因测试使医疗保健提供者能够根据个人的基因谱量身定制治疗计划，提高治疗效果并最大限度地减少副作用。基因检测结果可以指导针对特定呼吸系统疾病的标靶治疗的开发，从而产生更有效、更有针对性的治疗方案。

基因检测可以及早识别高风险族群，从而及时干预和製定个人化治疗计划。遗传图谱可以帮助临床医生选择最合适的治疗方法，最大限度地减少试验方法并改善患者的治疗结果。基因检测支持家庭筛检，以确定呼吸道疾病的遗传倾向并采取预防措施。

该报告研究了全球呼吸系统疾病基因检测市场，提供了市场概述、产品趋势、疾病类型、技术、性状类型、年龄层、最终用户、地区和市场。我们提供了进入市场的公司简介。

目录

第1章产品定义

第2章市场范围

第3章调查方法

  • 全球呼吸系统疾病基因检测市场：调查方法
  • 资料来源
  • 市场估算模型
  • 企业概况标准

第4章全球呼吸系统疾病基因检测市场：概述

第5章全球呼吸系统疾病基因检测市场：产业分析

  • 概述
  • 法律和法律规范
  • 产品平臺分析
  • 资金筹措方案（2019-2022）
  • 专利分析

第6章全球呼吸系统疾病基因检测市场：市场动态

  • 概述
  • 影响分析
  • 市场驱动因素
  • 市场抑制因素
  • 市场机会

第7章全球呼吸系统疾病基因检测市场：竞争形势

  • 概述
  • 协同效应
  • 产品发布和增强
  • 产品核准
  • 併购
  • 业务扩展和其他活动
  • 按公司分類的市场占有率分析（2022 年）
  • 成长份额分析

第8章全球呼吸系统疾病基因检测市场（依产品分类），2022-2033

  • 概述
  • 产品
  • 服务
  • 其他的

第9章全球呼吸系统疾病基因检测市场（依疾病类型），2022-2033

  • 概述
  • 慢性阻塞性肺病（α-1-抗胰蛋白酶 (AAT)）
  • 囊肿纤维化（CF）
  • 瀰漫性肺病/介面活性剂功能障碍
  • 间质性肺病
  • 肺动脉高血压
  • 肺发育不全
  • 原发性纤毛运动异常症
  • 其他疾病（BPD）

第10章全球呼吸系统疾病基因检测市场（按技术），2022-2033

  • 概述
  • PCR
  • NGS
  • 其他（标靶定序、核型分析、FISH）

第11章全球呼吸道疾病基因检测市场（依性状类型），2022-2033

  • 概述
  • 遗传特征
  • 后天的特征

第12章全球呼吸系统疾病基因检测市场（依年龄层），2022-2033

  • 概述
  • 儿童
  • 成人

第13章全球呼吸道疾病基因检测市场（依最终用户），2022-2033

  • 概述
  • 医院实验室
  • 诊断实验室
  • 基因检测实验室
  • 研究机构
  • 其他的

第14章2022-2033年全球呼吸道疾病基因检测市场（分地区）

  • 概述
  • 成长潜力分析（按国家）
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 其他地区

第15章公司简介

  • 23andMe, Inc.
  • Centogene AG
  • GeneDx, Inc.
  • Invitae Corporation
  • Color Genomics
  • Myriad Genetics
  • Medicover Genetics
  • Blueprint Genetics
  • Prevention Genetics
  • Quest Diagnostics
  • Genesis Genetics
  • ARUP Laboratories
  • EGL Genetic Diagnostics
  • Laboratory Corporation of America Holdings（LabCorp）
简介目录

Respiratory diseases continue to be a global health concern, with a significant impact on patient well-being and healthcare systems. Genetic testing has emerged as a crucial tool for understanding the genetic underpinnings of various respiratory conditions. This report provides an in-depth analysis of the global and regional trends in the respiratory disease genetic testing market, offering insights into market size, growth trends, regional disparities, and the impact of genetics on respiratory disease diagnostics and treatment.

Introduction

Respiratory diseases represent a diverse group of disorders, including asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and interstitial lung diseases, among others. The role of genetics in respiratory disease development and progression has become increasingly evident, leading to the growing importance of genetic testing in diagnosis, treatment, and prevention.

Market Overview

This section provides an overview of the global respiratory disease genetic testing market, including market size, growth trends, and key drivers.

Market Size and Growth

  • Factors contributing to this growth include the rising prevalence of respiratory diseases, advances in genetic testing technologies, and increasing awareness of personalized medicine.

Global Trends

  • Personalized Medicine: Genetic testing allows healthcare providers to tailor treatment plans to an individual's genetic profile, enhancing treatment efficacy and minimizing adverse effects.
  • Targeted Therapies: Genetic testing results are guiding the development of targeted therapies for specific respiratory diseases, leading to more effective and precise treatment options.
  • Genome-wide Association Studies (GWAS): Ongoing GWAS are identifying novel genetic markers associated with respiratory diseases, expanding our understanding of their genetic basis.

Impact on Diagnosis and Treatment

Genetic testing has a significant impact on the diagnosis and treatment of respiratory diseases.

  • Early Diagnosis: Genetic testing enables early identification of individuals at risk, allowing for timely intervention and personalized treatment plans.
  • Treatment Selection: Genetic profiles help clinicians choose the most suitable therapies, minimizing trial-and-error approaches and improving patient outcomes.
  • Family Screening: Genetic testing supports family screening to identify genetic predispositions to respiratory diseases, allowing for preventative measures.

Challenges and Opportunities

This section outlines the challenges and opportunities within the respiratory disease genetic testing market.

Challenges

  • Ethical and Privacy Concerns: The ethical use of genetic data and privacy concerns continue to be important considerations.
  • Access to Testing: Disparities in access to genetic testing services exist, affecting the equitable provision of care.

Opportunities

  • Advancements in Technology: Ongoing technological advancements are improving the accuracy and affordability of genetic testing.
  • Integration with Healthcare Systems: Integration with electronic health records and healthcare systems is streamlining the use of genetic information in clinical practice.

Table of Contents

1. Product Definition

  • 1.1. Inclusion and Exclusion

2. Market Scope

  • 2.1. Scope of Work
  • 2.2. Key Questions Answered in the Report

3. Research Methodology

  • 3.1. Global Respiratory Disease Genetic Testing Market: Research Methodology
  • 3.2. Data Sources
    • 3.2.1. Primary Data Sources
    • 3.2.2. Secondary Data Sources
  • 3.3. Market Estimation Model
  • 3.4. Criteria for Company Profiling

4. Global Respiratory Disease Genetic Testing Market: Overview

  • 4.1. Market Definition
  • 4.2. Market Footprint and Growth Potential
  • 4.3. Future Potential
  • 4.4. Genetic Surfactant Related Disorders
  • 4.5. Pulmonary Phenotypes and Related Genes
  • 4.6. Practical Issues of Genetic Testing for Respiratory Diseases
  • 4.7. Advantages and Disadvantages of Different Genetic Sequencing Approaches

5. Global Respiratory Disease Genetic Testing Market: Industry Analysis

  • 5.1. Overview
  • 5.2. Legal and Regulatory Framework
    • 5.2.1. Overview
    • 5.2.2. Regulatory Framework in the U.S.
    • 5.2.3. Regulatory Framework in the European Union
    • 5.2.4. Regulatory Framework in Asia
  • 5.3. Product Pipeline Analysis
    • 5.3.1. Overview
    • 5.3.2. By Companies
    • 5.3.3. By Developmental Phase
  • 5.4. Funding Scenario (2019-2022)
    • 5.4.1. Overview
    • 5.4.2. Institutional vs. Academic Funding
  • 5.5. Patent Analysis
    • 5.5.1. Overview
    • 5.5.2. By Country
    • 5.5.3. By Year

6. Global Respiratory Disease Genetic Testing Market: Dynamics

  • 6.1. Overview
  • 6.2. Impact Analysis
  • 6.3. Market Drivers
  • 6.4. Market Restraints
  • 6.5. Market Opportunities

7. Global Respiratory Disease Genetic Testing Market: Competitive Landscape

  • 7.1. Overview
  • 7.2. Synergistic Activities
  • 7.3. Product Launches and Enhancements
  • 7.4. Product Approvals
  • 7.5. Mergers and Acquisitions
  • 7.6. Business Expansion and Other Activities
  • 7.7. Market Share Analysis, By Company (2022)
  • 7.8. Growth Share Analysis
    • 7.8.1. By Application
    • 7.8.2. By Technology

8. Global Respiratory Disease Genetic Testing Market (by Offerings), 2022-2033, ($Million)

  • 8.1. Overview
  • 8.2. Products
    • 8.2.1. Kits and Consumables
  • 8.3. Services
  • 8.4. Others

9. Global Respiratory Disease Genetic Testing Market (by Disease Type), 2022-2033, ($Million)

  • 9.1. Overview
  • 9.2. COPD (Alpha-1-antitrypsin (AAT)
  • 9.3. Cystic Fibrosis (CF)
  • 9.4. Diffuse Lung Disease/Surfactant Dysfunction
    • 9.4.1. RHD (Respiratory Distress Syndrome)
    • 9.4.2. PPHN (Persistent Pulmonary Hypertension of the Newborn)
  • 9.5. Interstitial lung disease
  • 9.6. Pulmonary Arterial Hypertension
  • 9.7. Pulmonary Hypoplasia
  • 9.8. Primary Ciliary Dyskinesia
  • 9.9. Other Diseases (BPD)

10. Global Respiratory Disease Genetic Testing Market (by Technology), 2022-2033, ($Million)

  • 10.1. Overview
  • 10.2. PCR
  • 10.3. NGS
    • 10.3.1. Whole Genome Sequencing
    • 10.3.2. Whole Exome Sequencing
  • 10.4. Others (Targeted Sequencing, Karyotyping, and FISH)

11. Global Respiratory Disease Genetic Testing Market (by Trait Type), 2022-2033, ($Million)

  • 11.1. Overview
  • 11.2. Inherited Trait
  • 11.3. Acquired Trait

12. Global Respiratory Disease Genetic Testing Market (by Age Group), 2022-2033, ($Million)

  • 12.1. Overview
  • 12.2. Children Age Group
  • 12.3. Adult Age Group

13. Global Respiratory Disease Genetic Testing Market (by End User), 2022-2033, ($Million)

  • 13.1. Overview
  • 13.2. Hospital Laboratories
  • 13.3. Diagnostics Laboratories
  • 13.4. Genetic Testing Laboratories
  • 13.5. Research Laboratories
  • 13.6. Other End User

14. Global Respiratory Disease Genetic Testing Market (by Region), 2022-2033, ($Million)

  • 14.1. Overview
  • 14.2. Growth Potential Analysis (by Country)
  • 14.3. North America
    • 14.3.1. Key Dynamics
    • 14.3.2. U.S.
      • 14.3.2.1. By Application
      • 14.3.2.2. By Technology
    • 14.3.3. Canada
      • 14.3.3.1. By Application
      • 14.3.3.2. By Technology
  • 14.4. Europe
    • 14.4.1. Key Dynamics
    • 14.4.2. Italy
      • 14.4.2.1. By Application
      • 14.4.2.2. By Technology
    • 14.4.3. France
      • 14.4.3.1. By Application
      • 14.4.3.2. By Technology
    • 14.4.4. Russia
      • 14.4.4.1. By Application
      • 14.4.4.2. By Technology
    • 14.4.5. Germany
      • 14.4.5.1. By Application
      • 14.4.5.2. By Technology
    • 14.4.6. U.K.
      • 14.4.6.1. By Application
      • 14.4.6.2. By Technology
    • 14.4.7. Spain
      • 14.4.7.1. By Application
      • 14.4.7.2. By Technology
    • 14.4.8. Rest-of-Europe
  • 14.5. Asia-Pacific
    • 14.5.1. Key Dynamics
    • 14.5.2. China
      • 14.5.2.1. By Application
      • 14.5.2.2. By Technology
    • 14.5.3. Japan
      • 14.5.3.1. By Application
      • 14.5.3.2. By Technology
    • 14.5.4. India
      • 14.5.4.1. By Application
      • 14.5.4.2. By Technology
    • 14.5.5. Australia
      • 14.5.5.1. By Application
      • 14.5.5.2. By Technology
    • 14.5.6. Singapore
      • 14.5.6.1. By Application
      • 14.5.6.2. By Technology
    • 14.5.7. South Korea
      • 14.5.7.1. By Application
      • 14.5.7.2. By Technology
    • 14.5.8. Rest-of-Asia-Pacific
  • 14.6. Latin America
    • 14.6.1. Key Dynamics
    • 14.6.2. Brazil
      • 14.6.2.1. By Application
      • 14.6.2.2. By Technology
    • 14.6.3. Mexico
      • 14.6.3.1. By Application
      • 14.6.3.2. By Technology
    • 14.6.4. Rest-of-Latin America
  • 14.7. Rest-of-the-World
    • 14.7.1. Key Dynamics
    • 14.7.2. Middle East and Africa
      • 14.7.2.1. By Application
      • 14.7.2.2. By Technology
    • 14.7.3. Rest-of-Rest-of-the-World

15. Company Profiles

  • 15.1. Overview
  • 15.2. 23andMe, Inc.
  • 15.3. Centogene A.G.
  • 15.4. GeneDx, Inc.
  • 15.5. Invitae Corporation
  • 15.6. Color Genomics
  • 15.7. Myriad Genetics
  • 15.8. Medicover Genetics
  • 15.9. Blueprint Genetics
  • 15.10. Prevention Genetics
  • 15.11. Quest Diagnostics
  • 15.12. Genesis Genetics
  • 15.13. ARUP Laboratories
  • 15.14. EGL Genetic Diagnostics
  • 15.15. Laboratory Corporation of America Holdings (LabCorp)